Literature DB >> 25688733

Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey.

S C M Stoof1, H W van Steenbergen2, A Zwagemaker3, Y V Sanders1, S C Cannegieter4, J J Duvekot5, F W G Leebeek1, M Peters3, M J H A Kruip1, J Eikenboom2,6.   

Abstract

Pregnant women with bleeding disorders require specialised peripartum care to prevent postpartum haemorrhage (PPH). If third trimester coagulation factor levels are <0.50 IU mL(-1) , prophylactic treatment is indicated and administered according to international guidelines. However, optimal dose and duration are unknown and bleeding may still occur. The aim of this study was to investigate the outcome in women with von Willebrand disease (VWD) or haemophilia carriership treated according to current practice guidelines. From the period 2002-2011, 185 deliveries in 154 VWD women or haemophilia carriers were retrospectively included. Data on blood loss, bleeding disorder characteristics and obstetric risk factors were obtained. The outcome was primary PPH, defined as blood loss ≥500 mL within 24 h postpartum and severe PPH as blood loss ≥1000 mL. Primary PPH was observed in 62 deliveries (34%), 14 (8%) of which resulted in severe PPH. In 26 deliveries prophylactic treatment was administered due to factor levels below the 0.50 IU mL(-1) cut-off in the third trimester, 14 of which (54%) were complicated by PPH. We found an increased PPH risk in deliveries given prophylactic treatment compared with deliveries without (OR 2.7, 95% CI 1.2-6.3). In conclusion, PPH incidence was highest in deliveries with the lowest factor levels in the third trimester. Currently, delivery outcome in women with bleeding disorders is unsatisfactory, given the high PPH incidence despite specialised care. Future studies are required to optimise management of deliveries in this patient population.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  delivery; haemophilia A; haemophilia B; postpartum haemorrhage; prophylactic replacement therapy; von Willebrand disease

Mesh:

Substances:

Year:  2015        PMID: 25688733     DOI: 10.1111/hae.12635

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  20 in total

Review 1.  Haemostatic disorders in pregnancy.

Authors:  R Agarwala; C M Millar; J P Campbell
Journal:  BJA Educ       Date:  2020-03-18

2.  Bleeding severity in patients with rare bleeding disorders: real-life data from the RBiN study.

Authors:  Joline L Saes; Marieke J A Verhagen; Karina Meijer; Marjon H Cnossen; Roger E G Schutgens; Marjolein Peters; Laurens Nieuwenhuizen; Felix J M van der Meer; Ilmar C Kruis; Waander L van Heerde; Saskia E M Schols
Journal:  Blood Adv       Date:  2020-10-27

3.  Antifibrinolytic therapy for preventing VWD-related postpartum hemorrhage: indications and limitations.

Authors:  Peter A Kouides
Journal:  Blood Adv       Date:  2017-04-25

4.  Blood volume-based von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease.

Authors:  Margaret V Ragni
Journal:  Blood Adv       Date:  2017-04-25

5.  Blood type association with bleeding outcomes at delivery in a large multi-center study.

Authors:  Najeebah A Bade; Jamil M Kazma; Richard L Amdur; Julia Ellis-Kahana; Homa K Ahmadzia
Journal:  J Thromb Thrombolysis       Date:  2020-08       Impact factor: 2.300

Review 6.  Delivery and neuraxial technique outcomes in patients with hemophilia and in hemophilia carriers: a systematic review.

Authors:  Brandon M Togioka; Richard M Burwick; Jody L Kujovich
Journal:  J Anesth       Date:  2021-03-08       Impact factor: 2.078

7.  Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the hematologist's view.

Authors:  Margaret V Ragni
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 8.  Pregnancy in special populations: challenges and solutions practical aspects of managing von Willebrand disease in pregnancy.

Authors:  Ozlem Turan; Rezan Abdul Kadir
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 9.  Von Willebrand Disease: Current Status of Diagnosis and Management.

Authors:  Angela C Weyand; Veronica H Flood
Journal:  Hematol Oncol Clin North Am       Date:  2021-08-13       Impact factor: 3.722

10.  Recombinant vs plasma-derived von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease.

Authors:  Nicoletta Machin; Margaret V Ragni
Journal:  Blood Adv       Date:  2020-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.